Media release

From: JAMA

Assessing Efficacy of Ivermectin on Disease Progression in Patients With COVID-19

JAMA Internal Medicine
Original Investigation

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

What The Study Did: In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness didn’t reduce the risk of developing severe disease compared with standard care alone.

Authors: Steven Chee Loon Lim, M.R.C.P., of  the Raja Permaisuri Bainun Hospital in Perak, Malaysia, is the corresponding author.

(doi:10.1001/jamainternmed.2022.0189)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #